D.E. Shaw & Co
TPST icon

D.E. Shaw & Co’s Tempest Therapeutics TPST Stock Holding History

D.E. Shaw & Co’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-42
Closed -$112K – 3980
2018
Q2 		$112K Hold
42
– – ﹤0.01% 3608
2018
Q1 		$100K Sell
42
-41
-49% -$123K ﹤0.01% 3390
2017
Q4 		$341K Sell
83
-87
-51% -$365K ﹤0.01% 3186
2017
Q3 		$707K Buy
170
+28
+20% +$120K ﹤0.01% 2710
2017
Q2 		$648K Buy
142
+37
+35% +$157K ﹤0.01% 2677
2017
Q1 		$574K Buy
105
+26
+33% +$121K ﹤0.01% 2662
2016
Q4 		$354K Buy
79
+21
+36% +$262K ﹤0.01% 3046
2016
Q3 		$1.21M Buy
58
+43
+287% +$778K ﹤0.01% 2278
2016
Q2 		$236K Sell
15
-43
-74% -$982K ﹤0.01% 3131
2016
Q1 		$1.6M Buy
58
+20
+53% +$423K ﹤0.01% 2038
2015
Q4 		$1.09M Sell
38
-6
-14% -$198K ﹤0.01% 2581
2015
Q3 		$1.09M Sell
44
-12
-21% -$808K ﹤0.01% 2543
2015
Q2 		$4.72M Buy
56
+15
+37% +$1.37M 0.01% 1513
2015
Q1 		$4.17M Buy
+41
New +$5.46M 0.01% 1499

Other funds holding TPST

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co's TPST Position: Q3 2018 in Review

D.E. Shaw & Co sold out of Tempest Therapeutics (TPST) in Q3 2018, closing a stake of 42 shares — an estimated $112K sold.

D.E. Shaw & Co first reported a position in TPST in Q1 2015 and held it in 14 quarters. The position peaked at $4.72M in Q2 2015. 35 funds tracked by Wall St. Rank hold TPST as of Q3 2018.

  • D.E. Shaw & Co reported no remaining Tempest Therapeutics position as of Q3 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 42 Tempest Therapeutics shares in Q3 2018, an estimated $112K.
  • D.E. Shaw & Co first reported a position in Tempest Therapeutics in Q1 2015 and held it in 14 quarters.
  • D.E. Shaw & Co's Tempest Therapeutics position peaked at $4.72M in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2018.

Based on D.E. Shaw & Co's 13F filing for Q3 2018, filed 14 Nov 2018.